Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 8,147 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: GI Disorders Clear all
Completed Phase 2 Interventional

A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease

NCT00072943
View directory record Official record
Conditions
Crohn's Disease, Colitis, Intestinal Disease, Gastrointestinal Disease, Digestive System Disease
Interventions
anti-Interferon-gamma monoclonal antibody
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
15
States / cities
Anaheim, California • Orange, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

NCT04210115
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
Interventions
pembrolizumab, placebo, cisplatin, 5-FU, radiotherapy, leucovorin, levoleucovorin, oxaliplatin
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)

NCT01707225
View directory record Official record
Conditions
Gastrointestinal Bleeding
Interventions
Octreotide LAR Depot
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 24, 2026, 10:01 PM EDT
Terminated Phase 1 Interventional

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

NCT01705340
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 24, 2026, 10:01 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying

NCT07140289
View directory record Official record
Conditions
Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists, Intermittent Fasting, Intraoperative Complication Due to Anesthesia, Respiratory Aspiration of Gastric Contents
Interventions
Ultrasound of gastric contents
Diagnostic Test
Lead sponsor
Wael Saasouh, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer

NCT00025350
View directory record Official record
Conditions
Colorectal Cancer
Interventions
gefitinib
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
16
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 24, 2026, 10:01 PM EDT
Terminated Phase 2 Interventional Results available

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

NCT04383210
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions
Seribantumab
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 24, 2026, 10:01 PM EDT
Recruiting Phase 2 Interventional

PH 2 Pemigatinib in SDH-deficient GIST

NCT07434843
View directory record Official record
Conditions
SDH Gene Mutation, Gastrointestinal Stromal Tumor
Interventions
Pemigatinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Not applicable Interventional Results available

Evaluate the Use of Optical Frequency Domain Imaging (OFDI) for Celiac Disease in Children, Adolescents and Young Adults

NCT01439035
View directory record Official record
Conditions
Celiac Disease
Interventions
MGH OFDI Imaging
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

Survivorship Promotion In Reducing IGF-1 Trial

NCT02431676
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions
Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
Drug · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Not applicable Interventional

Acupuncture and Post-Operative Ileus

NCT00655317
View directory record Official record
Conditions
Ileus
Interventions
Acupuncture, Sham acupuncture
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 24, 2026, 10:01 PM EDT
Recruiting Not applicable Interventional

STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission

NCT06693310
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
de-escalation or discontinuation of therapy, continuation of current therapy
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 10:01 PM EDT
Recruiting Not applicable Interventional

EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope

NCT06340620
View directory record Official record
Conditions
Pancreatic Disease, Pancreatic Cancer, Pancreatic Cyst, Gastrointestinal Tumor, Bile Duct Diseases, Bile Duct Cancer, Lymph Node Disease, Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Cancer
Interventions
Endoscopic ultrasound examination
Device
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years to 100 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 10:01 PM EDT
Terminated Not applicable Interventional Results available

Endoscopic Mucosal Resection and Cellular Matrix

NCT03240679
View directory record Official record
Conditions
Barretts Esophagus With High Grade Dysplasia, Barrett Adenocarcinoma
Interventions
Acell MatriStem® Surgical Matrix
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Not applicable Interventional Results available

Treatment of IPF With Laparoscopic Anti-Reflux Surgery

NCT01982968
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Gastroesophageal Reflux
Interventions
Surgery
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

NCT04287868
View directory record Official record
Conditions
Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
Interventions
PDS0101, M7824, NHS-IL12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 24, 2026, 10:01 PM EDT
Completed No phase listed Observational

Follow-Up Phone Calls After Colorectal Surgery

NCT00474097
View directory record Official record
Conditions
Colorectal Surgery, Colorectal Neoplasms, Colitis, Ulcerative, Diverticulitis, Colonic Polyps
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)

NCT00390182
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Ovarian Neoplasms
Interventions
Gemcitabine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 24, 2026, 10:01 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach

NCT04685200
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 90 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 10:01 PM EDT
Completed No phase listed Observational

High Definition Single Cell Analysis in Colorectal Cancer

NCT02809716
View directory record Official record
Conditions
Metastatic Carcinoma in the Liver, Stage IV Colorectal Cancer
Interventions
Biomarker Analysis, Cytology Specimen Collection Procedure
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 24, 2026, 10:01 PM EDT
Active, not recruiting No phase listed Observational

A Cohort Study of the Intestinal Microbiota of Premature Infants

NCT03717584
View directory record Official record
Conditions
Necrotizing Enterocolitis, Bronchopulmonary Dysplasia, Growth Failure
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 33 Weeks
Enrollment
300 participants
Timeline
2018 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 1 Interventional

Fecal Transplant for Ulcerative Colitis

NCT03948919
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal microbiota, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 89 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

NCT00783692
View directory record Official record
Conditions
Crohn's Disease
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
110
States / cities
Birmingham, Alabama • Los Angeles, California • Montebello, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Not applicable Interventional

Pillars4Life Trial

NCT02465892
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Esophageal Cancer, Colon Cancer, Pancreatic Cancer, Liver Cancer, Renal Cancer, Bladder Cancer, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Pillars4Life
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 10:01 PM EDT